The Menopause Society | Menopause Society Certified Practitioner
Menopause Society Certified
Practitioner Examination 2026/2027 |
Verified Questions
The Menopause Society | Menopause Society Certified Practitioner | Professional Menopause Practitioner
Candidates
300 Verified Questions | 6 Core Domains | Academic Year 2026/2027
Prepared by
The Menopause Society | Menopause Society Certified Practitioner
MSCP Certification Examination Actual Exam | Academic Year 2026/2027
Menopause Society Certified Practitioner Examination 2026/2027 | Verified Questions
,INTRODUCTION
This document contains 300 Verified Questions covering the full MSCP Certification Examination, organised
into six core domains: (1) Physiology & Pathophysiology of the Menopause Transition; (2) Symptoms &
Concerns of Menopause; (3) Health Disorders in Midlife Women; (4) Therapeutic Options; (5) Preventive
Care & Counseling; (6) Comprehensive Review & Special Populations. Each question is designed to reinforce
the official The Menopause Society | Menopause Society Certified Practitioner MSCP Certification
Examination course objectives for actual exam readiness and menopause care proficiency, aligned to the
2026/2027 academic year and grounded in The Menopause Society curriculum, the STRAW+10 staging
system, NAMS/Menopause Society position statements, and current evidence-based clinical care standards
for midlife women.
ACTUAL QUESTIONS
Domain 1: Physiology & Pathophysiology of the Menopause Transition
Question 1. The STRAW+10 staging system for reproductive aging divides the female lifespan
into how many principal stages?
A. Three (pre-, peri-, post-).
B. Seven stages (–5 through +2), progressing from Reproductive (–5/–4/–3) to Menopausal Transition
(–2/–1) to Postmenopause (+1/+2), anchored by the final menstrual period (FMP).
C. Five (only reproductive through late postmenopause, excluding early).
D. Ten (based on decade of life).
Correct Answer: B
Rationale: The STRAW+10 (Stages of Reproductive Aging Workshop +10) staging system is the
international standard for describing reproductive aging across seven stages, anchored by the final
menstrual period (FMP at Stage 0). Stages –5 through –3 are reproductive, –2 through –1 mark the
menopausal transition (perimenopause), and +1 (early postmenopause) and +2 (late postmenopause)
follow. Criteria include menstrual cycle patterns, endocrine markers (FSH, AMH, inhibin B, antral follicle
count), and symptomatology.
Question 2. According to STRAW+10, the final menstrual period (FMP) is defined as:
A. The final menstrual period after which a woman has experienced 12 consecutive months of
amenorrhea with no other pathologic or physiologic cause.
B. The last period of a woman's reproductive life confirmed only by FSH >40 mIU/mL on one occasion.
C. The first skipped period after age 40.
D. Any period occurring after age 45.
Correct Answer: A
Rationale: STRAW+10 defines the FMP retrospectively after 12 consecutive months of amenorrhea, when
no other cause can be identified. FSH and AMH levels support staging but are not required for diagnosis in
women ≥45 with typical symptoms; cycle pattern is the primary criterion.
Question 3. Menopause is defined clinically as:
A. Cessation of menses for 3 months in a woman over 40.
B. FSH >20 mIU/mL on a single measurement at any age.
Menopause Society Certified Practitioner Examination 2026/2027 | Verified Questions
, C. Twelve consecutive months of amenorrhea in the absence of pathological causes, representing
permanent cessation of menstruation due to loss of ovarian follicular activity; the average age at natural
menopause is approximately 51–52 years.
D. Any irregularity in cycles after age 45.
Correct Answer: C
Rationale: Natural menopause is the permanent cessation of menstruation resulting from loss of ovarian
follicular activity, diagnosed retrospectively after 12 consecutive months of amenorrhea with no other
obvious pathologic/physiologic cause. Median age in Western populations is approximately 51–52 years;
timing is influenced by genetics, smoking, BMI, ethnicity, and prior chemotherapy/oophorectomy.
Question 4. Anti-Müllerian Hormone (AMH) reflects which aspect of ovarian physiology?
A. Endometrial receptivity for implantation.
B. The presence of corpus luteum in the current cycle.
C. Adrenal androgen production.
D. The size of the remaining primordial/antral follicle pool (ovarian reserve), produced by granulosa
cells of small growing pre-antral and early antral follicles.
Correct Answer: D
Rationale: AMH is secreted by granulosa cells of growing pre-antral and small antral follicles; levels
correlate with the remaining follicular pool. AMH declines with age, becoming very low/undetectable
postmenopause. It is cycle-independent and useful in assessing ovarian reserve but is not a direct marker
of timing of menopause at the individual level.
Question 5. During the menopausal transition, elevated early follicular FSH levels are largely
due to decreased secretion of which hormone by growing follicles?
A. Estradiol alone.
B. Inhibin B (and to a lesser degree inhibin A), secreted by granulosa cells, which normally suppress
pituitary FSH via negative feedback.
C. Progesterone.
D. Cortisol.
Correct Answer: B
Rationale: Inhibin B, produced by granulosa cells of small growing follicles, exerts pituitary negative
feedback selectively on FSH. As follicle numbers decline, inhibin B falls early in the menopausal transition
(Stage –2), reducing FSH suppression. Estradiol fluctuates widely during the transition and may be high in
early perimenopause before declining.
Question 6. The predominant circulating estrogen in postmenopausal women is:
A. Estradiol (E2).
B. Estriol (E3).
C. Ethinyl estradiol.
D. Estrone (E1), produced primarily by peripheral aromatization of androstenedione in adipose tissue.
Correct Answer: D
Menopause Society Certified Practitioner Examination 2026/2027 | Verified Questions
, Rationale: After menopause, ovarian estradiol production declines markedly. The dominant circulating
estrogen is estrone (E1), derived from peripheral aromatization of adrenal and ovarian androstenedione in
adipose tissue. Estrone concentrations exceed estradiol in postmenopause; estriol is the estrogen of
pregnancy.
Question 7. The ovary in postmenopausal women continues to produce which hormone(s) in
significant quantities?
A. High levels of estradiol.
B. Androgens, primarily testosterone and androstenedione (the latter largely from the adrenal cortex
with some ovarian contribution from theca/stromal cells).
C. Progesterone at luteal-phase concentrations.
D. AMH.
Correct Answer: B
Rationale: After menopause, the ovary's follicular activity ceases but the stroma/theca continue to produce
androgens (testosterone, androstenedione), driven in part by elevated LH. Adrenal DHEA/DHEAS also
contribute to the postmenopausal androgen pool. Estradiol levels fall to <20 pg/mL.
Question 8. Hot flushes (vasomotor symptoms) are believed to result primarily from:
A. Purely psychological stress with no physiologic basis.
B. Elevated thyroid hormone.
C. Altered thermoregulatory function in the hypothalamus related to declining/ fluctuating estrogen
levels affecting the thermoneutral zone, with narrowed thermoregulatory window leading to
inappropriate heat-loss responses (vasodilation/sweating).
D. Excess progesterone alone.
Correct Answer: C
Rationale: Vasomotor symptoms (VMS) are thought to arise from estrogen withdrawal/fluctuation
altering hypothalamic thermoregulation — narrowing the thermoneutral zone so small temperature
changes trigger exaggerated heat-loss responses: peripheral vasodilation, sweating, and the subjective
sensation of heat/flushing. Neurokinin B (NKB)/Kisspeptin signaling in the hypothalamus is implicated.
FSH elevation is a marker but not causal.
Question 9. Vulvovaginal atrophy (now termed Genitourinary Syndrome of Menopause, GSM)
results from:
A. Estrogen deficiency leading to thinning of vaginal epithelium, reduced glycogen, loss of lactobacillus
dominance, increased vaginal pH, decreased blood flow, reduced secretions, and atrophy of
vulvar/urethral tissues.
B. Bacterial vaginosis as the sole cause.
C. High estrogen states during pregnancy.
D. Excessive sexual activity.
Correct Answer: A
Rationale: GSM results from hypoestrogenism causing vulvovaginal and lower urinary tract changes:
vaginal dryness, dyspareunia, irritation, dysuria, urgency, recurrent urinary tract infections, and
decreased lubrication. Histology shows epithelial thinning, reduced glycogen, loss of lactobacilli, and
elevated vaginal pH (>5.0).
Menopause Society Certified Practitioner Examination 2026/2027 | Verified Questions
Menopause Society Certified
Practitioner Examination 2026/2027 |
Verified Questions
The Menopause Society | Menopause Society Certified Practitioner | Professional Menopause Practitioner
Candidates
300 Verified Questions | 6 Core Domains | Academic Year 2026/2027
Prepared by
The Menopause Society | Menopause Society Certified Practitioner
MSCP Certification Examination Actual Exam | Academic Year 2026/2027
Menopause Society Certified Practitioner Examination 2026/2027 | Verified Questions
,INTRODUCTION
This document contains 300 Verified Questions covering the full MSCP Certification Examination, organised
into six core domains: (1) Physiology & Pathophysiology of the Menopause Transition; (2) Symptoms &
Concerns of Menopause; (3) Health Disorders in Midlife Women; (4) Therapeutic Options; (5) Preventive
Care & Counseling; (6) Comprehensive Review & Special Populations. Each question is designed to reinforce
the official The Menopause Society | Menopause Society Certified Practitioner MSCP Certification
Examination course objectives for actual exam readiness and menopause care proficiency, aligned to the
2026/2027 academic year and grounded in The Menopause Society curriculum, the STRAW+10 staging
system, NAMS/Menopause Society position statements, and current evidence-based clinical care standards
for midlife women.
ACTUAL QUESTIONS
Domain 1: Physiology & Pathophysiology of the Menopause Transition
Question 1. The STRAW+10 staging system for reproductive aging divides the female lifespan
into how many principal stages?
A. Three (pre-, peri-, post-).
B. Seven stages (–5 through +2), progressing from Reproductive (–5/–4/–3) to Menopausal Transition
(–2/–1) to Postmenopause (+1/+2), anchored by the final menstrual period (FMP).
C. Five (only reproductive through late postmenopause, excluding early).
D. Ten (based on decade of life).
Correct Answer: B
Rationale: The STRAW+10 (Stages of Reproductive Aging Workshop +10) staging system is the
international standard for describing reproductive aging across seven stages, anchored by the final
menstrual period (FMP at Stage 0). Stages –5 through –3 are reproductive, –2 through –1 mark the
menopausal transition (perimenopause), and +1 (early postmenopause) and +2 (late postmenopause)
follow. Criteria include menstrual cycle patterns, endocrine markers (FSH, AMH, inhibin B, antral follicle
count), and symptomatology.
Question 2. According to STRAW+10, the final menstrual period (FMP) is defined as:
A. The final menstrual period after which a woman has experienced 12 consecutive months of
amenorrhea with no other pathologic or physiologic cause.
B. The last period of a woman's reproductive life confirmed only by FSH >40 mIU/mL on one occasion.
C. The first skipped period after age 40.
D. Any period occurring after age 45.
Correct Answer: A
Rationale: STRAW+10 defines the FMP retrospectively after 12 consecutive months of amenorrhea, when
no other cause can be identified. FSH and AMH levels support staging but are not required for diagnosis in
women ≥45 with typical symptoms; cycle pattern is the primary criterion.
Question 3. Menopause is defined clinically as:
A. Cessation of menses for 3 months in a woman over 40.
B. FSH >20 mIU/mL on a single measurement at any age.
Menopause Society Certified Practitioner Examination 2026/2027 | Verified Questions
, C. Twelve consecutive months of amenorrhea in the absence of pathological causes, representing
permanent cessation of menstruation due to loss of ovarian follicular activity; the average age at natural
menopause is approximately 51–52 years.
D. Any irregularity in cycles after age 45.
Correct Answer: C
Rationale: Natural menopause is the permanent cessation of menstruation resulting from loss of ovarian
follicular activity, diagnosed retrospectively after 12 consecutive months of amenorrhea with no other
obvious pathologic/physiologic cause. Median age in Western populations is approximately 51–52 years;
timing is influenced by genetics, smoking, BMI, ethnicity, and prior chemotherapy/oophorectomy.
Question 4. Anti-Müllerian Hormone (AMH) reflects which aspect of ovarian physiology?
A. Endometrial receptivity for implantation.
B. The presence of corpus luteum in the current cycle.
C. Adrenal androgen production.
D. The size of the remaining primordial/antral follicle pool (ovarian reserve), produced by granulosa
cells of small growing pre-antral and early antral follicles.
Correct Answer: D
Rationale: AMH is secreted by granulosa cells of growing pre-antral and small antral follicles; levels
correlate with the remaining follicular pool. AMH declines with age, becoming very low/undetectable
postmenopause. It is cycle-independent and useful in assessing ovarian reserve but is not a direct marker
of timing of menopause at the individual level.
Question 5. During the menopausal transition, elevated early follicular FSH levels are largely
due to decreased secretion of which hormone by growing follicles?
A. Estradiol alone.
B. Inhibin B (and to a lesser degree inhibin A), secreted by granulosa cells, which normally suppress
pituitary FSH via negative feedback.
C. Progesterone.
D. Cortisol.
Correct Answer: B
Rationale: Inhibin B, produced by granulosa cells of small growing follicles, exerts pituitary negative
feedback selectively on FSH. As follicle numbers decline, inhibin B falls early in the menopausal transition
(Stage –2), reducing FSH suppression. Estradiol fluctuates widely during the transition and may be high in
early perimenopause before declining.
Question 6. The predominant circulating estrogen in postmenopausal women is:
A. Estradiol (E2).
B. Estriol (E3).
C. Ethinyl estradiol.
D. Estrone (E1), produced primarily by peripheral aromatization of androstenedione in adipose tissue.
Correct Answer: D
Menopause Society Certified Practitioner Examination 2026/2027 | Verified Questions
, Rationale: After menopause, ovarian estradiol production declines markedly. The dominant circulating
estrogen is estrone (E1), derived from peripheral aromatization of adrenal and ovarian androstenedione in
adipose tissue. Estrone concentrations exceed estradiol in postmenopause; estriol is the estrogen of
pregnancy.
Question 7. The ovary in postmenopausal women continues to produce which hormone(s) in
significant quantities?
A. High levels of estradiol.
B. Androgens, primarily testosterone and androstenedione (the latter largely from the adrenal cortex
with some ovarian contribution from theca/stromal cells).
C. Progesterone at luteal-phase concentrations.
D. AMH.
Correct Answer: B
Rationale: After menopause, the ovary's follicular activity ceases but the stroma/theca continue to produce
androgens (testosterone, androstenedione), driven in part by elevated LH. Adrenal DHEA/DHEAS also
contribute to the postmenopausal androgen pool. Estradiol levels fall to <20 pg/mL.
Question 8. Hot flushes (vasomotor symptoms) are believed to result primarily from:
A. Purely psychological stress with no physiologic basis.
B. Elevated thyroid hormone.
C. Altered thermoregulatory function in the hypothalamus related to declining/ fluctuating estrogen
levels affecting the thermoneutral zone, with narrowed thermoregulatory window leading to
inappropriate heat-loss responses (vasodilation/sweating).
D. Excess progesterone alone.
Correct Answer: C
Rationale: Vasomotor symptoms (VMS) are thought to arise from estrogen withdrawal/fluctuation
altering hypothalamic thermoregulation — narrowing the thermoneutral zone so small temperature
changes trigger exaggerated heat-loss responses: peripheral vasodilation, sweating, and the subjective
sensation of heat/flushing. Neurokinin B (NKB)/Kisspeptin signaling in the hypothalamus is implicated.
FSH elevation is a marker but not causal.
Question 9. Vulvovaginal atrophy (now termed Genitourinary Syndrome of Menopause, GSM)
results from:
A. Estrogen deficiency leading to thinning of vaginal epithelium, reduced glycogen, loss of lactobacillus
dominance, increased vaginal pH, decreased blood flow, reduced secretions, and atrophy of
vulvar/urethral tissues.
B. Bacterial vaginosis as the sole cause.
C. High estrogen states during pregnancy.
D. Excessive sexual activity.
Correct Answer: A
Rationale: GSM results from hypoestrogenism causing vulvovaginal and lower urinary tract changes:
vaginal dryness, dyspareunia, irritation, dysuria, urgency, recurrent urinary tract infections, and
decreased lubrication. Histology shows epithelial thinning, reduced glycogen, loss of lactobacilli, and
elevated vaginal pH (>5.0).
Menopause Society Certified Practitioner Examination 2026/2027 | Verified Questions
